BMS-986258 + nivolumab

**BMS-986258 + nivolumab** is an investigational combination therapy composed of BMS-986258, a monoclonal antibody targeting the immune checkpoint TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), and nivolumab, a monoclonal antibody directed against the PD-1 (Programmed cell death protein 1) checkpoint[3][4][5][7]. The combination is designed as an immunotherapeutic approach for advanced, metastatic, or unresectable solid tumors, aiming to enhance anti-tumor immune responses by concurrently blocking two distinct immune checkpoints. Both molecules are biologics developed by Bristol Myers Squibb for use in cancers such as renal cell carcinoma, colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple-negative breast cancer, particularly in patients who have progressed after standard treatments[3][4][5][7].

Other names

BMS-986258 + nivolumabBMS-986258 in combination with nivolumabBMS986258 in combination with nivolumabBMS 986258 in combination with nivolumab